What they were paid
RECURSION PHARMACEUTICALS Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $46,958 | $306,246 | $378,401 | $0 | $731,605 |
| FY2024 | $0 | $0 | $0 | $0 | $0 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 30, 2026, accession 0001601830-26-000065, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themNominating/Governance · Research and Development · Technology
The rest of the RECURSION PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Blake Borgeson | Independent Director | $307,149 |
| Christopher Gibson | Chair of the Board | $0 |
| Dean Y. Li | Independent Director | $290,732 |
| Elaine Sun | Independent Director | $741,570 |
| Franziska Michor | Independent Director | $296,136 |
| Najat Khan | Director | $0 |
| Robert Hershberg | Lead Independent Director | $333,163 |
| Zachary Bogue | Independent Director | $0 |
| Zavain Dar | Independent Director | $308,160 |
The full RECURSION PHARMACEUTICALS compensation record
free company briefThis page is one director within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat